TL;DR
This study investigates the prognostic value of the 17-gene stemness score (LSC17) in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT). The findings reveal that a high LSC17 score at diagnosis is a significant predictor of worse overall survival, leukemia-free survival, and higher relapse rates post-HCT, highlighting its utility in risk stratification for this challenging patient group.
What Problem Does This Paper Address?
Acute myeloid leukemia (AML) is a complex blood cancer with diverse underlying biology, making it challenging to predict treatment response and long-term outcomes. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment, but a significant proportion of patients still relapse after HCT. Current risk stratification relies on factors like cytogenetics and molecular profiling, but these can be insufficient, especially for patients in the intermediate-risk category, leading to heterogeneous outcomes. There's a critical need for more precise tools to identify patients at high risk of relapse and poor survival post-HCT to guide treatment decisions and potentially enroll them in clinical trials for novel therapies. The 17-gene stemness score (LSC17) has previously shown promise in predicting outcomes for AML patients treated with standard chemotherapy, but its impact specifically in the context of HCT, a more intensive treatment, needed further investigation.
Methods
The study utilized a NanoString nCounter platform to measure gene expression from diagnostic bone marrow samples. The LSC17 score was calculated based on a previously established algorithm. Patients were categorized into "high" or "low" LSC17 score groups based on the median score from a reference cohort. Transplant outcomes, including overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and non-relapse mortality (NRM), were analyzed using Kaplan-Meier estimates and the cumulative incidence method for competing risks. Univariate and multivariate Cox proportional hazards models and Fine-Gray models were employed to assess the prognostic impact of the LSC17 score and other clinical factors. The study also explored the influence of conditioning regimen intensity and the development of graft-versus-host disease (GVHD) on transplant outcomes within the LSC17 score groups.
Datasets
The study analyzed data from 123 patients who received allogeneic HCT. These patients were drawn from two cohorts:
- Cohort 1: 80 patients diagnosed with AML between 2000 and 2012, retrospectively accrued.
- Cohort 2: 43 patients prospectively accrued between 2016 and 2018.
The LSC17 score was measured on diagnostic bone marrow samples. A reference cohort (n=908) was used to establish the median LSC17 score for classifying patients into high and low-risk groups.
Key Insights and Ideas
- LSC17 Score as a Post-HCT Prognosticator: The most significant insight is that the LSC17 score, measured before HCT, retains its prognostic power for predicting outcomes after HCT. This suggests that the underlying biological characteristics captured by the stemness score are not fully overcome by the transplantation process itself.
- Chronic GVHD as a Protective Factor: The study provides strong evidence that the development of chronic graft-versus-host disease (cGVHD) is associated with better overall survival and a reduced risk of relapse, even in patients with a high LSC17 score. This highlights the potential therapeutic role of the graft-versus-leukemia (GVL) effect mediated by cGVHD.
- Conditioning Intensity Doesn't Mitigate High LSC17 Risk: Interestingly, more intensive conditioning regimens (myeloablative vs. reduced-intensity) did not appear to improve outcomes for patients with a high LSC17 score, suggesting that the inherent biological aggressiveness of these leukemias is a primary driver of poor outcomes, not just the conditioning intensity.
- Need for Novel Strategies: The findings underscore that while HCT can improve outcomes, it may only partially overcome the adverse biology reflected by a high LSC17 score. This points to an urgent need for novel therapeutic strategies, potentially targeting the LSC17 pathway or leveraging GVL effects more effectively.
Key Results
- Overall Survival (OS) and Leukemia-Free Survival (LFS): Patients with a low LSC17 score had significantly better 2-year OS (56.4%) and LFS (51.2%) compared to those with a high LSC17 score (47.6% OS, 38.4% LFS). This difference was statistically significant (p=0.016 for OS, p=0.009 for LFS).
- Relapse Incidence (RI): The 2-year relapse rate was significantly lower in the low LSC17 score group (16.6%) compared to the high LSC17 score group (30.6%) (p=0.017).
- Non-Relapse Mortality (NRM): No significant difference in 2-year NRM was observed between the low and high LSC17 score groups (33.2% vs. 31.0%, p=0.682).
- Multivariate Analysis: The LSC17 score was confirmed as an independent prognostic factor for OS (HR 1.933) and LFS (HR 2.009) in multivariate analysis. It also showed a trend towards independent prognostic value for relapse risk.
- Chronic GVHD Benefit: Patients who developed chronic GVHD had significantly better overall survival (HR 0.427, p=0.012) across the entire cohort. This benefit was observed in both low and high LSC17 score groups.
Limitations and Future Work
- Retrospective Nature and Heterogeneity: The study acknowledges its retrospective nature and the heterogeneity of the patient cohort (two different time periods). The relatively small sample size also limits definitive conclusions, particularly for subgroup analyses.
- Validation: The observed outcomes have not yet been validated in an independent cohort.
- Intention-to-Treat: The study only included patients who received HCT, not those who did not, limiting its applicability to an intention-to-treat analysis.
- LSC17 Assay as a Research Tool: The NanoString assay for LSC17 is still considered a research tool, although it is undergoing development and evaluation in ongoing prospective studies.
- Future Work: The authors suggest that the LSC17 score could be incorporated into clinical decision-making for GVHD prophylaxis and post-transplant management. They also propose enrolling high-risk patients (identified by a high LSC17 score) in clinical trials to evaluate novel therapeutic strategies or refinements in current therapies. Further research into optimizing the LSC17 score's cut-off for HCT-specific cohorts and exploring specific gene combinations within the LSC17 signature are also suggested. The potential to induce a GVL effect, perhaps through donor lymphocyte infusions in the absence of cGVHD, is also mentioned as a future therapeutic avenue.
Summary updated